This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-27 and is reviewed periodically as new material appears.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Storage temperature | -20°C or below | Protect from light and moisture |
| Analytical method | RP-HPLC | Purity and identity assessment |
| Mass confirmation | Mass spectrometry | Verifies molecular mass |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
== Controversy == At the 68th AACC Annual Scientific Meeting in 2016, Elizabeth Holmes, CEO and founder of Theranos, spoke at what AACC described as a “special session.” Holmes, who the Centers for Medicare and Medicaid Services (CMS) had recently been banned from owning, operating or directing a blood testing service for a period of two years, was invited to present scientific data on her company's much discussed Edison device. Instead, Holmes took the opportunity to unveil a new product dubbed miniLab. Several people on the Theranos scientific advisory board were members of the association.
=== Opioid use disorder === Buprenorphine is used to treat people with opioid use disorder. In the U.S., the combination formulation of buprenorphine/naloxone is generally prescribed to deter injection, since naloxone, an opioid antagonist, is believed to cause acute withdrawal if the formulation is crushed and injected. Taken orally, the naloxone is still capable of blocking the rewarding effects of Buprenorphine. Especially given its combination with certain medications that can reduce the metabolism of naloxone. Before starting buprenorphine, individuals with opioid dependence are generally advised to wait after their last dose of opioid, often 24–72 hours, because if taken too soon buprenorphine can displace other opioids bound to the receptors and precipitate an acute withdrawal. The dose of buprenorphine is then adjusted until symptoms improve, and individuals remain on a maintenance dose, often 8–16 mg. Because withdrawal is uncomfortable and a deterrent for many patients, users have called for different means of treatment initiation. The Bernese method, also known as microdose induction, was described in 2016, where very small doses of buprenorphine (0.2 to 0.5 mg) are given while patients are still using street opioids, with medicine levels slowly titrated upward without precipitating withdrawal. This method has been used by some providers as of the 2020s. Many of the publications on the Bernese method are case reports, case series, or clinical guidance rather than large randomized controlled trials (RCTs).
=== DEA classification === Vicoprofen was initially scheduled as a schedule III drug, but was later reclassified to a schedule II drug based on the DEA reclassification of products containing hydrocodone, effective October 2014.
After transplantation, liver biopsy is the best method to monitor the evolution of post-transplant fibrosis, with significant fibrosis or portal hypertension one year after transplantation predicting rapid progression and graft loss and indicating the need for urgent intervention.
Nonlinear two-dimensional infrared spectroscopy is the infrared version of correlation spectroscopy. Nonlinear two-dimensional infrared spectroscopy is a technique that has become available with the development of femtosecond infrared laser pulses. In this experiment, first a set of pump pulses is applied to the sample. This is followed by a waiting time during which the system is allowed to relax. The typical waiting time lasts from zero to several picoseconds, and the duration can be controlled with a resolution of tens of femtoseconds. A probe pulse is then applied, resulting in the emission of a signal from the sample. The nonlinear two-dimensional infrared spectrum is a two-dimensional correlation plot of the frequency ω1 that was excited by the initial pump pulses and the frequency ω3 excited by the probe pulse after the waiting time. This allows the observation of coupling between different vibrational modes; because of its extremely fine time resolution, it can be used to monitor molecular dynamics on a picosecond timescale. It is still a largely unexplored technique and is becoming increasingly popular for fundamental research. As with two-dimensional nuclear magnetic resonance (2DNMR) spectroscopy, this technique spreads the spectrum in two dimensions and allows for the observation of cross peaks that contain information on the coupling between different modes. In contrast to 2DNMR, nonlinear two-dimensional infrared spectroscopy also involves the excitation to overtones.
Sources: en.wikipedia.org
=== Fusexin === The fusexin family consists of eukaryotic HAP2/GCS1, eukaryotic EFF-1, viral "class II", and haloarchaeal Fsx1. They all share a common fold and fuse membranes. In an unrooted phylogenetic tree from 2021, HAP2/GCS1 and EFF-1/AFF-1 occupy two ends of the tree, the middle being occupied by viral sequences; this suggests that they may have been acquired separately. The latest structure-based unrooted phylogenetic tree of Brukman et al. (2022), which takes into account the newly-discovered archaeal sequences, shows that Fsx1 groups with HAP2/GCS1, and that they are separated from EFF-1 by a number of viral sequences. Based on where the root is placed, a number of different hypotheses regarding the history of these families – their horizontal transfer and vertical inheritance – can be generated. Older comparisons excluding archaeal sequences would strongly favor an interpretation where HAP2/GCS1 is acquired from a virus, but the grouping of Fsx1 with HAP2/GCS1 has allowed the possibility of a much more ancient source.
CAS registry number – Chemical identifierPages displaying short descriptions of redirect targets Chemical nomenclature – Systematic naming of chemical compounds Commission on Isotopic Abundances and Atomic Weights – International scientific committee European Association for Chemical and Molecular Sciences Institute for Reference Materials and Measurements (IRMM) – Promotes a common European measurement system International Chemical Identifier (InChI) – Identifier for chemical substances International Union of Biochemistry and Molecular Biology (IUBMB) – International non-governmental organization International Union of Pure and Applied Physics (IUPAP) – Non-governmental organization for physics development List of chemical elements naming controversies National Institute of Standards and Technology (NIST) – Measurement standards laboratory in the United States Simplified molecular-input line-entry system (SMILES) – Chemical species structure notationPages displaying short descriptions of redirect targets
== Mechanism == A CI experiment involves the use of gas phase acid-base reactions in the chamber. Some common reagent gases include: methane, ammonia, water and isobutane. Inside the ion source, the reagent gas is present in large excess compared to the analyte. Electrons entering the source will mainly ionize the reagent gas because it is in large excess compared to the analyte. The primary reagent ions then undergo secondary ion/molecule reactions (as below) to produce more stable reagent ions which ultimately collide and react with the lower concentration analyte molecules to form product ions. The collisions between reagent ions and analyte molecules occur at close to thermal energies, so that the energy available to fragment the analyte ions is limited to the exothermicity of the ion-molecule reaction. For a proton transfer reaction, this is just the difference in proton affinity between the neutral reagent molecule and the neutral analyte molecule. This results in significantly less fragmentation than does 70 eV electron ionization (EI). The following reactions are possible with methane as the reagent gas.
=== Notable cases === As of April 2016, six hyperthymesia cases have been confirmed in peer-reviewed articles, the first being that of Jill Price (initially anonymised as "AJ") in 2006. More cases had been identified by 2012, but are yet to be published. Price's case was originally reported by researchers from the University of California, Irvine, Elizabeth Parker, Larry Cahill and James McGaugh, and is credited as being the first documented case of hyperthymesia. Price can apparently recall every day of her life from when she was 14 years old: "Starting on February 5, 1980, I remember everything. That was a Tuesday." In March 2009, Price was interviewed for an article in Wired magazine by Gary Marcus, a cognitive psychologist at New York University. Price's brain had been subject to a brain scan and the hippocampus and prefrontal cortex had been reportedly normal. Marcus claimed, however, that her brain resembled "those of people with obsessive-compulsive disorder" and suggested that her remarkable memory might be "the byproduct of obsession", claiming also that "the memory woman clings tightly to her past". Price strongly disputed this and McGaugh has also challenged the explanation. Price gave her first interview in over a year for the UK's Channel 4 documentary The Boy Who Can't Forget, and spoke of the challenges of living with the condition. K.
Sources: en.wikipedia.org
=== Synthetic ionophores === Many synthetic ionophores are based on crown ethers, cryptands, and calixarenes. Pyrazole-pyridine and bis-pyrazole derivatives have also been synthesized. These synthetic species are often macrocyclic. Some synthetic agents are not macrocyclic, e.g. carbonyl cyanide-p-trifluoromethoxyphenylhydrazone. Even simple organic compounds, such as phenols, exhibit ionophoric properties. The majority of synthetic receptors used in the carrier-based anion-selective electrodes employ transition elements or metalloids as anion carriers, although simple organic urea- and thiourea-based receptors are known.
Imaging compounds, notably Pittsburgh compound B, (6-OH-BTA-1, a thioflavin), can selectively bind to amyloid beta in vitro and in vivo. This technique, combined with PET imaging, is used to image areas of plaque deposits in those with Alzheimer's.
Throughout the 15th and 16th centuries, Portuguese explorers sailed the coast of Africa, established trading posts [[Economic history of Portugal#Expansion of the Portuguese empire (15th and 16th centuries)|for commodities]] especially gold and slaves, explored the Indian Ocean and eastern Asia, and established trade routes in most of southern Asia, taxing most trade criss-crossing the Indian Ocean. However, by the 16th century its enterprise in Asia was already in decline. The 1494 Treaty of Tordesillas divided newly encountered non-European territories between Portugal and Spain along a meridian west of Cape Verde, while the 1529 Treaty of Zaragoza extended this partition to the Pacific Ocean. In 1498, Vasco da Gama reached India by sea, and two years later Pedro Álvares Cabral landed in Brazil and claimed it for Portugal. During the 15th century, Portugal established the transatlantic slave-trade circuits and, by the mid-19th century, had become one of the longest-active and a significant participant in the Atlantic slave trade.
Sources: en.wikipedia.org
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.
Lyophilized powder should be stored at -20°C or lower, protected from light and moisture. Reconstituted solutions are less stable and should be aliquoted to avoid freeze-thaw cycles. Always follow supplier instructions.
Variability in purity, counterion content, and residual solvents is possible. Independent testing and certificates of analysis help verify quality. Microbial contamination can occur if handling is not sterile.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.